Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC).

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples